Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
作者： Bianca Devitt , Wendy Liu , Renato Salemi , Rory Wolfe , John Kelly
DOI: 10.1111/J.1755-148X.2011.00873.X
关键词:
摘要: The effect of NRAS mutations on the pathological features and clinical outcomes in patients with cutaneous melanoma was compared that tumors containing BRAF(V600E) wild type for both (WT). Clinical outcome data were obtained from a prospective cohort 249 patients. Mutations involving detected by PCR sequence verified. Cox proportional hazards regression performed to relate BRAF outcome. Seventy-five percentage occurred >1 mm thick (BRAF(V600E) 40%, WT 34%); 75% had mitosis/mm(2) 55%). When WT, multivariate analysis melanoma-specific survival (MSS) identified as an adverse prognostic factor [hazard ratio (HR) 2.96; P = 0.04] but not (HR 1.73; 0.23). associated thicker higher rates mitosis when independently this, shorter MSS.
sci-hub.se 参考文章(29)
R. W. Joseph, R. J. Sullivan, D. Panka, G. Manoukian, A. Percy, R. Harrell, R. L. Bassett, M. B. Atkins, P. Hwu, M. A. Davies, Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma. Journal of Clinical Oncology. ,vol. 28, pp. 8597- 8597 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.8597
Lars A. Akslen, Sabrina Angelini, Oddbjørn Straume, Ingeborg M. Bachmann, Anders Molven, Kari Hemminki, Rajiv Kumar, BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival Journal of Investigative Dermatology. ,vol. 125, pp. 312- 317 ,(2005) , 10.1111/J.0022-202X.2005.23788.X
Pablo Rodriguez-Viciana, Patricia H. Warne, Ritu Dhand, Bart Vanhaesebroeck, Ivan Gout, Michael J. Fry, Michael D. Waterfield, Julian Downward, PHOSPHATIDYLINOSITOL-3-OH KINASE AS A DIRECT TARGET OF RAS Nature. ,vol. 370, pp. 527- 532 ,(1994) , 10.1038/370527A0
Despina Handolias, Renato Salemi, William Murray, Angela Tan, Wendy Liu, Amaya Viros, Alexander Dobrovic, John Kelly, Grant A. McArthur, Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure Pigment Cell & Melanoma Research. ,vol. 23, pp. 210- 215 ,(2010) , 10.1111/J.1755-148X.2010.00671.X
R. D. Carvajal, P. B. Chapman, J. D. Wolchok, L. Cane, J. B. Teitcher, J. Lutzky, A. C. Pavlick, B. C. Bastian, C. R. Antonescu, G. K. Schwartz, A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT Journal of Clinical Oncology. ,vol. 27, pp. 9001- 9001 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.9001
Tom Crosby, Reg Fish, Bernadette Coles, Malcolm Mason, Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews. ,vol. 2018, ,(2000) , 10.1002/14651858.CD001215
Kari Hemminki, Kamila Czene, Ilari Sauroja, Seppo Pyrhönen, Sabrina Angelini, Rajiv Kumar, Marjo Hahka-Kemppinen, BRAF Mutations in Metastatic Melanoma: A Possible Association with Clinical Outcome Clinical Cancer Research. ,vol. 9, pp. 3362- 3368 ,(2003)
David Dankort, David P Curley, Robert A Cartlidge, Betsy Nelson, Anthony N Karnezis, William E Damsky Jr, Mingjian J You, Ronald A DePinho, Martin McMahon, Marcus Bosenberg, BrafV600E cooperates with Pten loss to induce metastatic melanoma Nature Genetics. ,vol. 41, pp. 544- 552 ,(2009) , 10.1038/NG.356
Carole Peyssonnaux, Alain Eychène, The Raf/MEK/ERK pathway: new concepts of activation Biology of the Cell. ,vol. 93, pp. 53- 62 ,(2001) , 10.1016/S0248-4900(01)01125-X
P J Mishra, L Ha, J Rieker, E V Sviderskaya, D C Bennett, M D Oberst, K Kelly, G Merlino, Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation Oncogene. ,vol. 29, pp. 2449- 2456 ,(2010) , 10.1038/ONC.2009.521